Badalian Gayane, Derecskei Katalin, Szendroi Attila, Szendroi Miklós, Tímár József
Department of Orthopaedics, Semmelweis University, Budapest.
Anticancer Res. 2007 Mar-Apr;27(2):889-94.
EGFR and VEGFR2 protein expressions are hallmarks of clear cell renal cancer (RCC) with questionable prognostic impact. The skeletal system is one of the most common metastatic sites of RCC. Unfortunately, there are no data for EGFR and VEGFR2 protein expression in such lesions.
Twenty cases of bone metastatic clear cell RCC were analyzed. EGFR and VEGFR2 proteins were detected by immunohistochemistry and analyzed by morphometry scoring both % positivity and the intensity.
EGFR protein scores were significantly reduced in bone metastases of RCC due to the reduction of EGFR protein expression in about one third of the cases (7/20). The VEGFR2 protein-positive phenotype of clear cell RCC was relatively frequent (7/20, 35%), but was lost in bone metastases (2/20, 10%).
These data suggest a phenotypic/genotypic change of clear cell RCC during the progression to bones and warrant further investigation.
表皮生长因子受体（EGFR）和血管内皮生长因子受体2（VEGFR2）蛋白表达是透明细胞肾细胞癌（RCC）的特征，其预后影响存在疑问。骨骼系统是RCC最常见的转移部位之一。遗憾的是，尚无此类病变中EGFR和VEGFR2蛋白表达的数据。
分析20例骨转移性透明细胞RCC病例。通过免疫组织化学检测EGFR和VEGFR2蛋白，并通过形态计量学分析阳性百分比和强度。
由于约三分之一的病例（7/20）中EGFR蛋白表达降低，RCC骨转移中EGFR蛋白评分显著降低。透明细胞RCC的VEGFR2蛋白阳性表型相对常见（7/20，35%），但在骨转移中消失（2/20，10%）。
这些数据表明透明细胞RCC在向骨转移进展过程中存在表型/基因型变化，值得进一步研究。
Zotero 插件